"Medvi has engaged in a range of dishonest marketing practices, including using AI-deepfaked images of phony patients and misleadingly flaunting media logos."
"The New York Times profile either downplayed or omitted glaring ethical red flags surrounding Medvi's marketing practices and its use of AI-fabricated images."
"At the time of the NYT article's publication, Medvi was being marketed on social media by accounts featuring clearly fake doctors."
"In February 2026, the FDA issued a warning to Medvi LLC, pointing to multiple violations on its Medvi-branded site, Medvi.io."
Medvi is a drug marketing company that operates as a marketing wrapper for telehealth services, particularly for GLP-1 agonists. The New York Times published a profile praising Medvi, but it faced significant backlash for ethical concerns. Medvi has been accused of using AI-generated images of fake patients and misleading marketing tactics. The NYT article downplayed these issues and falsely claimed that Medvi stopped using AI-fabricated client photos. Additionally, the FDA issued a warning to Medvi for multiple violations related to its marketing practices.
Read at Futurism
Unable to calculate read time
Collection
[
|
...
]